Dr. Volker Diehl is well known for his pioneering research on Hodgkin lymphoma. His scientific achievements include the discovery of the causative role of the Epstein-Barr virus in infectious mononucleosis and the study of its association with Hodgkin lymphoma. He also cultured the first notoriously fragile Hodgkin cell lines and led the development of BEACOPP, a chemotherapy regimen for the treatment of Hodgkin lymphoma. Dr. Diehl has received much recognition for his work, including the German Johann Georg Zimmermann Prize for Cancer Research, and is Chairman of the German Hodgkin Lymphoma Study Group, one of the largest Hodgkin studies in the world, which he founded in 1978. He is also an honorary member of the Moscow Academy of Medicine, the European Society of Radio-Oncology, the Belgian Society of Radio-Oncology, the German Society of Radio-Oncology, the Hungarian Society of Hematology, and the German Society of Internal Medicine.
Dr. Diehl has published numerous articles in the Society's journal Blood.
back to top